Serum selenium predicts achievement of full-dose cisplatin in concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: A prospective, observational study. (October 2021)
- Record Type:
- Journal Article
- Title:
- Serum selenium predicts achievement of full-dose cisplatin in concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: A prospective, observational study. (October 2021)
- Main Title:
- Serum selenium predicts achievement of full-dose cisplatin in concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: A prospective, observational study
- Authors:
- Ohkoshi, Akira
Ishii, Ryo
Wakamori, Shun
Nakayama, Yuki
Yoshida, Takuya
Higashi, Kenjiro
Nakanome, Ayako
Ogawa, Takenori
Katori, Yukio - Abstract:
- Highlights: Selenium deficiency is a potential therapeutic target in head and neck cancer. Selenium deficiency affects the achievement of full-dose cisplatin in CCRT. Baseline renal function affects the achievement of full-dose cisplatin in CCRT. Abstract: Objective: Concurrent chemoradiotherapy (CCRT) with three-weekly high-dose cisplatin (100 mg/m 2 ) is a standard treatment for locally advanced head and neck squamous cell carcinoma (HNSCC), but compliance with cisplatin is often poor due to various adverse events. The aim of this prospective, observational study was to determine the predictors of achievement of full-dose cisplatin. Methods: A prospective, observational study was conducted involving 60 patients who received CCRT with three-weekly high-dose cisplatin (100 mg/m 2 ) for locally advanced HNSCC. Possible predictors affecting compliance with cisplatin were subjected to univariate and multivariate logistic regression analyses. Age, sex, primary site, clinical stage, treatment intent, history of hypertension, diabetes mellitus, smoking and drinking habits, body mass index, creatinine clearance, serum albumin, controlling nutrition status, trace elements (Fe, Zn, Cu, Se), acute kidney injury, white blood cell count decrease, neutrophilia, and weight loss were the variables evaluated. Results: Twenty-seven patients achieved full-dose cisplatin (300 mg/m 2 ), and the other 33 patients did not. Multivariate logistic regression analysis showed that both mild renalHighlights: Selenium deficiency is a potential therapeutic target in head and neck cancer. Selenium deficiency affects the achievement of full-dose cisplatin in CCRT. Baseline renal function affects the achievement of full-dose cisplatin in CCRT. Abstract: Objective: Concurrent chemoradiotherapy (CCRT) with three-weekly high-dose cisplatin (100 mg/m 2 ) is a standard treatment for locally advanced head and neck squamous cell carcinoma (HNSCC), but compliance with cisplatin is often poor due to various adverse events. The aim of this prospective, observational study was to determine the predictors of achievement of full-dose cisplatin. Methods: A prospective, observational study was conducted involving 60 patients who received CCRT with three-weekly high-dose cisplatin (100 mg/m 2 ) for locally advanced HNSCC. Possible predictors affecting compliance with cisplatin were subjected to univariate and multivariate logistic regression analyses. Age, sex, primary site, clinical stage, treatment intent, history of hypertension, diabetes mellitus, smoking and drinking habits, body mass index, creatinine clearance, serum albumin, controlling nutrition status, trace elements (Fe, Zn, Cu, Se), acute kidney injury, white blood cell count decrease, neutrophilia, and weight loss were the variables evaluated. Results: Twenty-seven patients achieved full-dose cisplatin (300 mg/m 2 ), and the other 33 patients did not. Multivariate logistic regression analysis showed that both mild renal dysfunction and selenium deficiency before treatment independently had negative impacts on achievement of full-dose cisplatin. Conclusions: As well as renal function, selenium deficiency is a potential therapeutic target for CCRT with high-dose cisplatin in HNSCC patients. … (more)
- Is Part Of:
- Oral oncology. Volume 121(2021)
- Journal:
- Oral oncology
- Issue:
- Volume 121(2021)
- Issue Display:
- Volume 121, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 121
- Issue:
- 2021
- Issue Sort Value:
- 2021-0121-2021-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-10
- Subjects:
- Head and neck cancer -- Concurrent chemoradiotherapy -- Cisplatin -- Selenium -- Trace elements -- Renal insufficiency
CCRT concurrent chemoradiotherapy -- HNSCC head and neck squamous cell carcinoma -- AKI acute kidney injury -- CONUT controlling nutrition status -- KDIGO kidney disease improving global outcomes
Mouth -- Cancer -- Periodicals
Mouth -- Tumors -- Periodicals
Mouth Diseases -- Periodicals
Mouth Neoplasms -- Periodicals
Bouche -- Cancer -- Périodiques
Bouche -- Tumeurs -- Périodiques
Tumeurs -- Périodiques
Electronic journals
616.9943105 - Journal URLs:
- http://www.sciencedirect.com/science/journal/13688375 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/13688375 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.oraloncology.2021.105475 ↗
- Languages:
- English
- ISSNs:
- 1368-8375
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6277.592000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19122.xml